Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia

Endocrine Journal

Volumn 54, Issue 1, 2007, Pages 53-58

  Yamakawa, Tadashi ^a   Takano, Tatsuro ^a   Utsunomiya, Hirotoshi ^b   Kadonosono, Kazuaki ^a   Okamura, Atushi ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood glucose; Colestimide; Diabetes mellitus; Hemoglobin A1c

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; COLESTILAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EPICHLOROHYDRIN; FEMALE; HEMOGLOBINS; HUMANS; HYPERCHOLESTEROLEMIA; IMIDAZOLES; INSULIN RESISTANCE; MALE; MIDDLE AGED; PRAVASTATIN; RESINS, SYNTHETIC;

EID: 33947610582     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K05-098     Document Type: Article

References (25)

1. Turner RC, Millns H, Neil HA, Stratton I M, Manley SE, Matthews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828.
2. Heart Protection Study Group (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 23-33.
3. Heart Protection Study Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 7-22.
4. The Lipid Research Clinics Coronary Primary Prevention Trial Results II (1984) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374.
5. Crouse JR 3rd (1987) Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 83: 243-248.
6. Mitsuka M, Hashimoto M, Takizawa T, Shimada H, Suzuki Y, Umezu K (1996) Hypolipidemic effects of MCI-196, a novel anion exchange resin, in rabbits. Jpn Pharmacol Ther 24: s585-594.
7. MCI-196 Study Group (1996) Study on the usefulness of MCI-1996 in patients with hypercholesterolemia. Rinsho Iyaku 12: 1641-1692.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364: 685-696.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
10. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R (2005) Acute onset and worsening of diabetes concurrent with administration of statins. Endocr J 52: 369-372.
11. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A (2006) Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 13: 95-100.
12. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357-362.
13. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen HA (1996) Prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19: 1138-1141.
14. Mooradian AD, Morley JE, Levine AS, Prigge WF, Gebhard RL (1986) Abnormal intestinal permeability to sugars in diabetes mellitus. Diabetologia 29: 221-224.
15. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP (2005) Regulation of carbohydrate metabolism by the farnesoid x receptor. Endocrinology 146: 984-991.
16. Urizar NL, Moore DD (2003) GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 23: 303-313.
17. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703-1706.
18. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messadde N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
19. Kajiyama G, Tzazuma S, Yamashita G (1996) Effect of MIC-196 on biliary lipids metabolism in patients with hypercholesterolemia. Rinsho Iyaku 12: 1349-1359.
20. UK Prospective Diabetes Study Group. U.K. (1995) Prospective Diabetes Study Group 16: overview of 6 year' therapy of type II diabetes: progressive disease. Diabetes 44: 1249-1258.
21. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS33). Lancet 352: 837-853.
22. UK Prospective Diabetes Study Group. U.K. (1998) Prospective Diabetes Study 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type2 diabetes. Diabetes Care 21: 87-92.
23. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287: 360-372.
24. Krepinsky J, Ingram AJ, Clase CM (2000) Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35: 500-505.
25. The lipid Research Clinics Coronary Primary Prevention Trial Results. I (1984) Reduction in incidence of coronary heart disease. JAMA 251: 351-364.